Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | June 01, 2010 | June 02, 2010 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date June 01, 2010 · Filed June 02, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $34.24 · Expires 2020-05-31 | Direct | 40,000 |
Reported balance
After 2010-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2010-06-01 · Grant · Acquired 40,000 · Balance 40,000 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2010 Filed Jun 2, 2010 19:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 40,000 | $0.00 Strike: $34.24 | $0.00 |
DisclosureSEC source: 0000875320-10-000026 · edgar.xml · derivative · entry 1 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2020-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2009 Filed Jun 3, 2009 18:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 40,000 | $0.00 Strike: $29.89 | $0.00 |
DisclosureSEC source: 0000875320-09-000038 · edgar.xml · derivative · entry 1 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires 2019-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| May 18, 2009 Filed May 19, 2009 18:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 3,333 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000875320-09-000029 · edgar.xml · derivative · entry 3 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2009-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| May 18, 2009 Filed May 19, 2009 18:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,333 | $28.44 | $94,790.52 |
DisclosureSEC source: 0000875320-09-000029 · edgar.xml · nonDerivative · entry 2 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,383 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a wieghted averae price of $28.44 (range $28.11 to $28.93). F3 · price: Dr. Sanders undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 18, 2009 Filed May 19, 2009 18:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,333 | $10.05 | $33,496.65 |
DisclosureSEC source: 0000875320-09-000029 · edgar.xml · nonDerivative · entry 1 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2009 Filed May 12, 2009 18:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 3,333 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000875320-09-000028 · edgar.xml · derivative · entry 3 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2009-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| May 11, 2009 Filed May 12, 2009 18:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,333 | $30.41 | $101,356.53 |
DisclosureSEC source: 0000875320-09-000028 · edgar.xml · nonDerivative · entry 2 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,383 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a wieghted averae price of $30.41 (range $29.99 to $30.63). F3 · price: Dr. Sanders undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2009 Filed May 12, 2009 18:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,333 | $10.05 | $33,496.65 |
DisclosureSEC source: 0000875320-09-000028 · edgar.xml · nonDerivative · entry 1 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2009 Filed May 5, 2009 16:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 3,334 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000875320-09-000023 · edgar.xml · derivative · entry 3 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 3,334 shares Expires 2009-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| May 04, 2009 Filed May 5, 2009 16:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,334 | $30.08 | $100,286.72 |
DisclosureSEC source: 0000875320-09-000023 · edgar.xml · nonDerivative · entry 2 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,383 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a wieghted averae price of $30.08 (range $29.85 to $30.50). F3 · price: Dr. Sanders undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2009 Filed May 5, 2009 16:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,334 | $10.05 | $33,506.70 |
DisclosureSEC source: 0000875320-09-000023 · edgar.xml · nonDerivative · entry 1 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2008 Filed Jun 2, 2008 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $28.40 | $0.00 |
DisclosureSEC source: 0000875320-08-000036 · edgar.xml · derivative · entry 1 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2018-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 3,333 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0000875320-08-000033 · edgar.xml · derivative · entry 11 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2008-05-31 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, fully vested on grant date, 6/1/1998. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.16 | $9,044.28 |
DisclosureSEC source: 0000875320-08-000033 · edgar.xml · nonDerivative · entry 10 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,383 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $26.99 | $8,987.67 |
DisclosureSEC source: 0000875320-08-000033 · edgar.xml · nonDerivative · entry 9 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,716 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 334 | $26.84 | $8,964.56 |
DisclosureSEC source: 0000875320-08-000033 · edgar.xml · nonDerivative · entry 8 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,049 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $26.75 | $8,907.75 |
DisclosureSEC source: 0000875320-08-000033 · edgar.xml · nonDerivative · entry 7 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,383 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $26.71 | $8,894.43 |
DisclosureSEC source: 0000875320-08-000033 · edgar.xml · nonDerivative · entry 6 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,716 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 666 | $26.68 | $17,768.88 |
DisclosureSEC source: 0000875320-08-000033 · edgar.xml · nonDerivative · entry 5 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,049 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 334 | $26.66 | $8,904.44 |
DisclosureSEC source: 0000875320-08-000033 · edgar.xml · nonDerivative · entry 4 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,715 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 334 | $26.54 | $8,864.36 |
DisclosureSEC source: 0000875320-08-000033 · edgar.xml · nonDerivative · entry 3 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,049 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $26.40 | $8,791.20 |
DisclosureSEC source: 0000875320-08-000033 · edgar.xml · nonDerivative · entry 2 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,383 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 27, 2008 Filed May 28, 2008 17:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,333 | $14.20 | $47,328.60 |
DisclosureSEC source: 0000875320-08-000033 · edgar.xml · nonDerivative · entry 1 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 3,333 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0000875320-08-000027 · edgar.xml · derivative · entry 11 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires 2008-05-31 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, fully vested on grant date, 6/1/1998. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.67 | $9,214.11 |
DisclosureSEC source: 0000875320-08-000027 · edgar.xml · nonDerivative · entry 10 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,383 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 334 | $27.47 | $9,174.98 |
DisclosureSEC source: 0000875320-08-000027 · edgar.xml · nonDerivative · entry 9 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,716 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.46 | $9,144.18 |
DisclosureSEC source: 0000875320-08-000027 · edgar.xml · nonDerivative · entry 8 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,050 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.73 | $9,234.09 |
DisclosureSEC source: 0000875320-08-000027 · edgar.xml · nonDerivative · entry 7 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,383 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 667 | $27.71 | $18,482.57 |
DisclosureSEC source: 0000875320-08-000027 · edgar.xml · nonDerivative · entry 6 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,716 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.61 | $9,194.13 |
DisclosureSEC source: 0000875320-08-000027 · edgar.xml · nonDerivative · entry 5 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,383 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.59 | $9,187.47 |
DisclosureSEC source: 0000875320-08-000027 · edgar.xml · nonDerivative · entry 4 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,716 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 333 | $27.58 | $9,184.14 |
DisclosureSEC source: 0000875320-08-000027 · edgar.xml · nonDerivative · entry 3 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,049 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 334 | $27.50 | $9,185.00 |
DisclosureSEC source: 0000875320-08-000027 · edgar.xml · nonDerivative · entry 2 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,382 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved sales plan established under Rule 10b5-1. Read SEC document |
| May 20, 2008 Filed May 21, 2008 19:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,333 | $14.20 | $47,328.60 |
DisclosureSEC source: 0000875320-08-000027 · edgar.xml · nonDerivative · entry 1 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2008 Filed May 19, 2008 18:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $27.51 | $0.00 |
DisclosureSEC source: 0000875320-08-000026 · edgar.xml · derivative · entry 1 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2018-05-14 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 3,334 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0000875320-08-000020 · edgar.xml · derivative · entry 11 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 3,334 shares Expires 2008-05-31 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, fully vested on grant date, 6/1/1998. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 334 | $27.70 | $9,251.80 |
DisclosureSEC source: 0000875320-08-000020 · edgar.xml · nonDerivative · entry 10 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,383 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $27.46 | $8,238.00 |
DisclosureSEC source: 0000875320-08-000020 · edgar.xml · nonDerivative · entry 9 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,717 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $27.27 | $8,181.00 |
DisclosureSEC source: 0000875320-08-000020 · edgar.xml · nonDerivative · entry 8 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,017 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $27.19 | $13,595.00 |
DisclosureSEC source: 0000875320-08-000020 · edgar.xml · nonDerivative · entry 7 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,317 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $27.13 | $8,139.00 |
DisclosureSEC source: 0000875320-08-000020 · edgar.xml · nonDerivative · entry 6 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,817 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $27.08 | $5,416.00 |
DisclosureSEC source: 0000875320-08-000020 · edgar.xml · nonDerivative · entry 5 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,117 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $27.07 | $10,828.00 |
DisclosureSEC source: 0000875320-08-000020 · edgar.xml · nonDerivative · entry 4 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,317 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $27.03 | $8,109.00 |
DisclosureSEC source: 0000875320-08-000020 · edgar.xml · nonDerivative · entry 3 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,717 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $27.00 | $18,900.00 |
DisclosureSEC source: 0000875320-08-000020 · edgar.xml · nonDerivative · entry 2 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,017 F1 · kind: Transaction made pursuant to Dr. Sanders' company approved trading plan established under Rule 10b5-1. Read SEC document |
| May 13, 2008 Filed May 15, 2008 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,334 | $14.20 | $47,342.80 |
DisclosureSEC source: 0000875320-08-000020 · edgar.xml · nonDerivative · entry 1 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2007 Filed Jun 4, 2007 16:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $29.84 | $0.00 |
DisclosureSEC source: 0000875320-07-000058 · edgar.xml · derivative · entry 2 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2017-05-31 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| May 31, 2007 Filed Jun 4, 2007 16:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $29.84 | $0.00 |
DisclosureSEC source: 0000875320-07-000058 · edgar.xml · derivative · entry 1 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2017-05-30 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan. Fully vested. Read SEC document |
| May 07, 2007 Filed May 8, 2007 18:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $19.78 | $0.00 |
DisclosureSEC source: 0000875320-07-000043 · edgar.xml · derivative · entry 3 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2007-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan. Fully vested. Read SEC document |
| May 07, 2007 Filed May 8, 2007 18:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,000 | $30.53 | $305,300.00 |
DisclosureSEC source: 0000875320-07-000043 · edgar.xml · nonDerivative · entry 2 SANDERS CHARLES A · CIK 0001022936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,383 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.